Swedish biotech company Atrogi AB has dosed the first subjects in a new human trial of ATR-258, an oral pill designed to burn fat stored inside skeletal muscle while preserving muscle mass and leaving appetite largely unchanged. The drug works through a mechanism never before tested in people: it selectively activates a signaling branch of the beta-2 adrenergic receptor tied to fat oxidation in muscle, while avoiding the cardiac and appetite-related side effects that have derailed earlier drugs targeting the same receptor. If the approach holds up in larger trials, it could offer a fundamentally different path for treating type 2 diabetes and obesity, one that does not rely on suppressing hunger or accepting the muscle loss that accompanies current weight-loss medications.
How GRK2-biased signaling separates ATR-258 from older fat-burning drugs
The core scientific claim behind ATR-258 rests on a distinction in receptor biology. Traditional beta-2 adrenergic agonists activate the receptor broadly, triggering fat metabolism but also raising heart rate and causing tremors. ATR-258, identified in the peer-reviewed literature as compound 15, takes a different route. It is a GRK2-biased partial agonist of the beta-2 receptor, meaning it preferentially engages a signaling arm mediated by the enzyme GRK2 rather than the classical G-protein pathway responsible for much of the cardiovascular stimulation.
That selectivity matters for a specific reason. When muscle cells retain their full mass and contractile function during fat oxidation, the tissue continues to act as a major site of glucose disposal. Skeletal muscle is responsible for the bulk of insulin-stimulated glucose uptake in the body. Drugs that cause muscle wasting, including some high-dose GLP-1 receptor agonists, can erode this glucose sink even as they reduce body weight. A therapy that burns intramuscular fat without shrinking the muscle itself could, in theory, deliver greater improvements in insulin sensitivity per unit of fat lost.
Preclinical work underlying ATR-258 suggests that GRK2-biased beta-2 signaling can decouple fat burning from the adverse effects historically seen with this receptor class. In animal models and ex vivo muscle preparations, compound 15 increased fatty acid oxidation and improved glucose control without the same degree of tachycardia or tremor that accompanies non-selective beta-2 agonists. Those data, combined with receptor-signaling studies, formed the rationale for moving the compound into human testing and for positioning it as a metabolic drug rather than a cardiovascular agent or general stimulant.
Phase 1 results and the next round of human dosing
ATR-258 has already completed a Phase 1 first-in-human trial. The study, registered on ClinicalTrials.gov as NCT05409924 and titled ATTRACTIVE 1, enrolled both healthy participants and participants with type 2 diabetes. Atrogi AB sponsored the trial, which used single and multiple ascending doses to evaluate safety, tolerability, and basic pharmacokinetics.
Atrogi has reported positive clinical data from the Phase 1a/b portion of that trial, describing ATR-258 as well tolerated and noting early metabolic signals. According to a perspective published in Signal Transduction and Targeted Therapy, part of the Nature Portfolio, compound 15 was tolerated in Phase 1 and its GRK2-biased mechanism was highlighted as a way to avoid the cardiac side effects that limited earlier beta-2 agonists. Together, these early human data and mechanistic insights support the idea that selective signaling can broaden the therapeutic window for beta-2–based drugs.
Building on those results, Atrogi has now moved to a new study focused specifically on muscle physiology. The company announced that first subjects have been dosed in this trial, which is designed to explore how ATR-258 affects intramuscular fat, muscle function, and markers of insulin sensitivity. The new study is closely tied to the mechanistic work reported in a June 2025 Cell publication that describes the foundational science behind the drug and characterizes compound 15 as a GRK2-biased beta-2 agonist with muscle-targeted metabolic effects.
Monash University, a collaborating institution on the research, has confirmed that ATR-258 corresponds to compound 15 and stated that the drug burns fat and reduces blood sugar while preserving muscle mass. The ongoing human study aims to translate those preclinical findings into quantitative readouts in people, using imaging and metabolic testing to assess whether similar patterns emerge in vivo.
What researchers need to show in the new muscle-focused trial
The evidence so far is encouraging but narrow. The completed Phase 1 trial established that ATR-258 did not cause serious safety problems at the doses tested and supported further development. What it did not establish, at least not in any publicly posted dataset, is whether the drug meaningfully changes fat oxidation rates, glucose levels, or body composition in a controlled clinical setting. The ClinicalTrials.gov record for ATTRACTIVE 1 lists metabolic endpoints but contains no posted results or statistical outputs, leaving outside observers dependent on sponsor summaries and secondary commentary.
To move beyond that stage, the muscle-physiology trial now underway will need to deliver several types of evidence. First, investigators must demonstrate that intramuscular fat content decreases in participants receiving ATR-258 compared with those on placebo, ideally in a dose-dependent fashion. Techniques such as MRI-based fat quantification or spectroscopy could provide those measurements, alongside biopsies in a subset of volunteers. Second, they will need to show that these structural changes correlate with functional improvements in insulin sensitivity, for example through clamp studies or standardized glucose tolerance tests.
Equally important will be documenting what does not happen. A central promise of GRK2-biased beta-2 signaling is that it avoids the spikes in heart rate, blood pressure, and subjective jitteriness associated with older beta-2 agonists. Careful cardiovascular monitoring, including ambulatory heart-rate tracking and electrocardiography, will be critical for confirming that the safety window observed in early Phase 1 holds up over longer dosing periods and in a more metabolically vulnerable population.
Positioning against GLP-1 drugs and remaining unknowns
Atrogi’s press materials position ATR-258 as distinct from GLP-1 receptor agonists such as semaglutide, which suppress appetite and cause significant weight loss but also reduce lean muscle mass. That framing speaks to a real clinical concern: rapid weight loss that disproportionately affects muscle can undermine long-term metabolic health and physical function, particularly in older adults with type 2 diabetes.
However, no head-to-head metabolic data comparing ATR-258 with GLP-1–based therapies currently exist. The assertion that GRK2-biased signaling will outperform unbiased beta-2 agonists on insulin sensitivity, specifically because muscle is preserved, remains a hypothesis grounded in receptor biology and preclinical models rather than in definitive clinical proof. Likewise, it is not yet clear whether ATR-258 will produce substantial overall weight loss, modest body recomposition without large changes on the scale, or mainly improvements in glycemic control at relatively stable body weight.
Regulators and clinicians will also be watching for longer-term safety signals that may not emerge in short, early-phase studies. Chronic modulation of beta-2 receptors in muscle could, in theory, lead to receptor desensitization, shifts in fiber type, or unknown off-target effects. The Cell paper and related mechanistic work provide reassurance that the GRK2-biased profile is distinct from classical beta-agonist pharmacology, but only extended clinical observation can determine whether that translates into durable safety and efficacy.
For now, ATR-258 represents a carefully constructed experiment in human receptor signaling: can selectively activating a fat-burning pathway in skeletal muscle improve metabolic health without the trade-offs that have dogged both stimulant-like drugs and appetite suppressants? The next data readout from Atrogi, particularly from the muscle-focused trial now dosing subjects, will determine whether this strategy can move beyond basic safety testing and toward the kind of robust metabolic outcomes needed to change the treatment landscape for type 2 diabetes and obesity.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
